Epsilogen
Develops antibody-based cancer treatments, including a clinical candidate for ovarian cancer
Highlights
- New on EvolcAdded 2026-10-28
About Epsilogen
Epsilogen is a clinical-stage biotechnology company developing IgE, IgA and IgG antibody therapeutics for cancer. Its platforms include bispecific IgE and IgEG antibodies.
Its lead candidate, MOv18 IgE, targets folate receptor alpha and is being studied in a phase Ib trial in patients with platinum-resistant ovarian cancer. It completed a phase I trial in ovarian cancer.
Epsilogen was founded in 2016 and is headquartered in London.
Product: Antibody therapeutics in development, including MOv18 IgE and bispecific IgE and IgEG platforms.
Jobs at Epsilogen
No open positions listed right now.
Leadership
- Tim Wilson · Chief Executive OfficerSource: company website
- Nick Robbins-Cherry · Chief Financial OfficerSource: company website
- Leanne Partington · VP of Product DevelopmentSource: company website
More biotech & pharma companies
Extracellular
CDMO for cell-based food, cosmetics and materials products, offering bioprocess development and up to 2,000L manufacturingNew on EvolcSalary transparentExymes
Enzyme-based DNA/RNA extraction reagents and kits for forensic, academic, veterinary and environmental labsYoung companyNew on EvolcF2G
Develops first-in-class antifungal medicines for rare, life-threatening fungal infections in patients with limited optionsNew on EvolcFlyttr
Pest biosecurity platform with sensors, AI decision-support and biological countermeasures for governments and agricultureNew on EvolcFortress Diagnostics
In vitro diagnostic tests and reagents for clinical laboratories, healthcare providers and research institutions worldwideNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Cloudflare
- Google Tag Manager
- Google reCAPTCHA
- WordPress
- jQuery
- nginx